Conquering egg allergy with eggs

Article

It seems the best way to conquer egg allergy in children is with eggs. Find out how researchers in a clinical trial showed how to rid most children of the sensitivity and achieved a sustained clinical effect.

It seems the best way to conquer egg allergy in children is with eggs, according to a recent multicenter, double-blind, randomized trial.

The study adds to the growing body of research demonstrating that oral immunotherapy not only desensitizes children with food allergy (ie, raises the threshold at which a reaction occurs) but also provides sustained clinical effect in a high proportion of children with allergies to foods such as milk, peanuts, and eggs.

Researchers included in their study 55 children aged 5 to 11 years (median age, 7 years) with egg allergy, defined as the development of symptoms within minutes to 2 hours after ingestion and a serum egg-specific IgE antibody level of more than 5 kU per liter in children aged 6 years or older or 12 kU per liter or more for those aged 5 years. Forty of the children received daily oral immunotherapy; the other 15 received placebo.

After 10 months of therapy, 55% of the immunotherapy group and none of the placebo group passed an oral food challenge of 5 g of egg-white powder. After 22 months, 75% of those who passed the first food challenge passed the second food challenge of 10 g of egg-white powder. Of the 30 children passing the second food challenge, 29 underwent the oral food challenge at 24 months; 11 passed.

Thus, 11 of 40 (28%) in the immunotherapy group achieved not just desensitization but also “sustained unresponsiveness,” or the ability, after almost 2 years of oral immunotherapy and subsequent avoidance of eggs for 4 to 6 weeks, to consume 10 g of egg-white powder and a whole cooked egg without any clinically significant symptoms. These children successfully incorporated egg into their diet; 11 reported no adverse events at 30 months. Ten reported no adverse events at 3 years.

Reactions, when they occurred, were mostly mild; 1% of reactions were graded moderate. Approximately 15% of the participants who received oral immunotherapy did not complete the therapy, in most cases because of allergic reactions.

Go back to the current issue of the eConsult.

Recent Videos
David Turkewitz, MD
H. Westley Phillips, MD
David Turkewitz, MD
Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH
Paul Helmuth, MD
Brittany Bruggeman, MD
Octavio Ramilo
Melissa Fickey, MD
© 2024 MJH Life Sciences

All rights reserved.